Organization | SK Bioscience Co., Ltd.

SK Bioscience Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Seongnam Korea, Republic of (2001)

Organization Overview

First Clinical Trial

2018

NCT03704740

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

SK Bioscience | SK Bioscience Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (10)

as03 (2 trials)

chadox1 (1 trial)

gbp510 (4 trials)

human rotavirus, live attenuated (Rotarix) (2 trials)

inactivated influenza vaccine (1 trial)

tv p2-vp8 (1 trial)

typbar (1 trial)

typhoid vi polysaccharide vaccine (Typhim Vi) (1 trial)

vi-dt typhoid conjugate vaccine (1 trial)

Drugs in Phase 2 Trials (5)

aluminum hydroxide (Gaviscon) (2 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

nbp615 (1 trial)

rv3-bb (1 trial)

trivalent p2-vp8 (1 trial)

Drugs in Phase 1 Trials (1)

nbp2001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Gastroenteritis (Phase 3)

Influenza, Human (Phase 3)

Rotavirus Infections (Phase 3)

Typhoid Fever (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 16